SCHEMBL3967355

SCHEMBL3967355

CCc1cc(C)nnc1NC(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 4/20 0.38
HTT P42858 3/20 0.38
NPC1 O15118 3/20 0.38
ATM Q13315 2/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
ADORA1 P30542 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA9 Q16790 1/20 0.35
CNR2 P34972 1/20 0.34
GAA P10253 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966666 0.89 L3MBTL1 (0.36) L3MBTL1SMN1; SMN2RAB9AHTTNPC1
SCHEMBL4694453 0.86 S1PR1 (0.38) L3MBTL1SMN1; SMN2RAB9AHTTNPC1
SCHEMBL3965245 0.81 HTT (0.42) L3MBTL1SMN1; SMN2RAB9AHTTNPC1
SCHEMBL3926799 0.79 ATM (0.37) L3MBTL1SMN1; SMN2RAB9AHTTNPC1
SCHEMBL3966602 0.77 ATM (0.36) L3MBTL1SMN1; SMN2RAB9AHTTNPC1
SCHEMBL3969946 0.76 GAA (0.50) L3MBTL1HTTATMMEN1KMT2A
SCHEMBL3964910 0.74 ADORA1 (0.43) L3MBTL1SMN1; SMN2RAB9AHTTNPC1
SCHEMBL21119857 0.73 GAA (0.48) KMT2AKDM4EALDH1A1MAPTCNR2
SCHEMBL3963052 0.72 TMIGD3 (0.38) L3MBTL1SMN1; SMN2RAB9AHTTNPC1
SCHEMBL21736983 0.68 GRIN2D (0.34) KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557103-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-07-07 US disclosed
US-20080153828-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-06-26 US disclosed
EP-1879896-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2008-01-23 EP disclosed
WO-2006107784-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153828-A1 Imidazopyridazine Compounds CRHR1, CRH, CRHR2 L3MBTL1 4787/4885SMN1; SMN2 1787/4885RAB9A 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.